Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor | Zendy

John O. Prior | Zendy; Michael Montemurro | Zendy; Maria-Victoria Orcurto | Zendy; Olivier Michielin | Zendy; François Lüthi | Zendy; Jean Benhattar | Zendy; Louis Guillou | Zendy; Valérie Elsig | Zendy; Roger Stupp | Zendy; Angelika Bischof Delaloye | Zendy; Serge Leyvraz | Zendy

Open Access

Early Prediction of Response to Sunitinib After Imatinib Failure by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor

Author(s) -

John O. Prior,

Michael Montemurro,

Maria-Victoria Orcurto,

Olivier Michielin,

François Lüthi,

Jean Benhattar,

Louis Guillou,

Valérie Elsig,

Roger Stupp,

Angelika Bischof Delaloye,

Serge Leyvraz

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.17.2742

Subject(s) - sunitinib , medicine , positron emission tomography , response evaluation criteria in solid tumors , gist , progressive disease , imatinib , fluorodeoxyglucose , standardized uptake value , imatinib mesylate , nuclear medicine , clinical endpoint , tyrosine kinase inhibitor , progression free survival , gastroenterology , oncology , cancer , stromal cell , chemotherapy , clinical trial , myeloid leukemia

Positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) was used to evaluate treatment response in patients with gastrointestinal stromal tumors (GIST) after administration of sunitinib, a multitargeted tyrosine kinase inhibitor, after imatinib failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research